An open-label study to assess the long-term effects of rasagiline on cumulative disability in Parkinson\'s disease: design and baseline data from the ADAGIO follow-up study
Prof. Fabrizio Stocchi
Disclosure : This study is supported by Teva Pharmaceutical Industries Ltd (Israel), Teva Neuroscience Inc (USA) and H.Lundbeck A/S (Denmark).
Prof. Stocchi reports consulting fees from Teva, Lundbeck, GlaxoSmithKline, Boehringer Ingleheim, Newron, Merck Serono, Novartis, Impax, Schering Plaugh, Chiesi pharma and UCB.
16 slide(s) – English – 2011-09-10